Skip to main content
TRAW
NASDAQ Life Sciences

Traws Pharma Defers Lead Influenza Drug Study After Negative UK Regulatory Review

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Negative
Importance info
9
Price
$1.01
Mkt Cap
$19.393M
52W Low
$0.995
52W High
$3.265
52W Position info
1.5% above low
Off High info
69% below high
Rel. Volume info
0.2× avg
Market data snapshot near publication time

TRAW is trading near its 52-week low of $0.995 (1.5% above the low) on light trading volume (0.2× avg).

Summary

Traws Pharma announced the deferral of a planned Phase 2a human influenza study for its lead candidate, tivoxavir marboxil, due to a negative review from the UK's MHRA, marking a significant setback for the clinical-stage company.


Key Events · Product Development and Regulatory · TRAW

  • Lead Program Deferred

    The planned Phase 2a human influenza challenge study for tivoxavir marboxil (TXM) has been deferred.

  • Negative Regulatory Review

    The deferral is a direct result of a negative review of the program by the United Kingdom's Medicines and Healthcare Products Regulatory Agency (MHRA).

  • Impact on Pipeline

    This setback affects a key clinical program for the company, which is focused on developing novel therapies for viral threats.

  • Mitigation Strategy

    Traws Pharma is advancing alternative influenza antiviral compounds and maintains that TXM retains potential for emergency use.


Analysis · TRAW · Life Sciences

This is a critical setback for Traws Pharma, a clinical-stage biopharmaceutical company already facing a 'going concern' warning and zero revenue. The deferral of a Phase 2a study for its lead influenza candidate, tivoxavir marboxil, due to a negative regulatory review directly impacts its core development pipeline and future revenue potential. While the company is pursuing alternative candidates, this news, especially with the stock trading near 52-week lows, significantly increases the pressure to achieve clinical milestones and secure future financing.

How filings like this one have moved

In the 30 days to Nov 17, 2026, 52.4% of the 208 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -1.91%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, TRAW was trading at $1.01 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $19.4M. The 52-week trading range was $1.00 to $3.27. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

TRAW - Latest Insights

TRAW
Nov 16, 2026, 4:58 PM EST
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $0.240
Real-time Price: $0.1768 info
Change: -$0.0632 (-26%) info
Market Cap: $2.737M info
TRAW
Nov 16, 2026, 4:45 PM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $0.240
Real-time Price: $0.1768 info
Change: -$0.0632 (-26%) info
Market Cap: $2.737M info
TRAW
Nov 12, 2026, 7:00 AM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $0.252
Real-time Price: $0.1768 info
Change: -$0.0752 (-30%) info
Market Cap: $2.737M info
TRAW
Oct 26, 2026, 4:47 PM EDT
Filing Type: S-1
Importance Score:
8
Price at Filing: $0.350
Real-time Price: $0.1768 info
Change: -$0.1732 (-49%) info
Market Cap: $2.737M info
TRAW
Oct 23, 2026, 5:18 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $0.3425
Real-time Price: $0.1768 info
Change: -$0.1657 (-48%) info
Market Cap: $2.737M info